128 related articles for article (PubMed ID: 8168080)
1. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
ten Hoeve J; Kaartinen V; Fioretos T; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Cancer Res; 1994 May; 54(10):2563-7. PubMed ID: 8168080
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
Oncogene; 1997 Feb; 14(5):507-13. PubMed ID: 9053848
[TBL] [Abstract][Full Text] [Related]
3. C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells.
de Jong R; van Wijk A; Heisterkamp N; Groffen J
Oncogene; 1998 Nov; 17(21):2805-10. PubMed ID: 9840945
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of murine Crkl.
de Jong R; Haataja L; Voncken JW; Heisterkamp N; Groffen J
Oncogene; 1995 Oct; 11(8):1469-74. PubMed ID: 7478571
[TBL] [Abstract][Full Text] [Related]
5. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
Cho YJ; Hemmeryckx B; Groffen J; Heisterkamp N
Biochem Biophys Res Commun; 2005 Aug; 333(4):1276-83. PubMed ID: 15982636
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Grb2 and Crkl proteins results in growth inhibition of Philadelphia chromosome positive leukemic cells.
Tari AM; Arlinghaus R; Lopez-Berestein G
Biochem Biophys Res Commun; 1997 Jun; 235(2):383-8. PubMed ID: 9199202
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Matulonis U; Salgia R; Okuda K; Druker B; Griffin JD
Exp Hematol; 1993 Oct; 21(11):1460-6. PubMed ID: 8405226
[TBL] [Abstract][Full Text] [Related]
8. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.
Sattler M; Salgia R; Okuda K; Uemura N; Durstin MA; Pisick E; Xu G; Li JL; Prasad KV; Griffin JD
Oncogene; 1996 Feb; 12(4):839-46. PubMed ID: 8632906
[TBL] [Abstract][Full Text] [Related]
9. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
10. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia.
de Jong R; ten Hoeve J; Heisterkamp N; Groffen J
J Biol Chem; 1995 Sep; 270(37):21468-71. PubMed ID: 7545163
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
ten Hoeve J; Arlinghaus RB; Guo JQ; Heisterkamp N; Groffen J
Blood; 1994 Sep; 84(6):1731-6. PubMed ID: 7521685
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
13. A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Mizutani T; Kondo T; Darmanin S; Tsuda M; Tanaka S; Tobiume M; Asaka M; Ohba Y
Clin Cancer Res; 2010 Aug; 16(15):3964-75. PubMed ID: 20670950
[TBL] [Abstract][Full Text] [Related]
14. CRKL binding to BCR-ABL and BCR-ABL transformation.
Kolibaba KS; Bhat A; Heaney C; Oda T; Druker BJ
Leuk Lymphoma; 1999 Mar; 33(1-2):119-26. PubMed ID: 10194128
[TBL] [Abstract][Full Text] [Related]
15. Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
Patel H; Marley SB; Greener L; Gordon MY
Leukemia; 2008 Mar; 22(3):559-71. PubMed ID: 18059481
[TBL] [Abstract][Full Text] [Related]
16. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
[TBL] [Abstract][Full Text] [Related]
17. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
Salgia R; Uemura N; Okuda K; Li JL; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen LB
J Biol Chem; 1995 Dec; 270(49):29145-50. PubMed ID: 7493940
[TBL] [Abstract][Full Text] [Related]
18. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
[TBL] [Abstract][Full Text] [Related]
19. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
Grumbach IM; Mayer IA; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish EN; Platanias LC
Br J Haematol; 2001 Feb; 112(2):327-36. PubMed ID: 11167825
[TBL] [Abstract][Full Text] [Related]
20. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
Nichols GL; Raines MA; Vera JC; Lacomis L; Tempst P; Golde DW
Blood; 1994 Nov; 84(9):2912-8. PubMed ID: 7524758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
